|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM153006234 |
| 003 |
DE-627 |
| 005 |
20231223063143.0 |
| 007 |
tu |
| 008 |
231223s2005 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0510.xml
|
| 035 |
|
|
|a (DE-627)NLM153006234
|
| 035 |
|
|
|a (NLM)15639652
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a van der Vliet, Hans J J
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients
|
| 264 |
|
1 |
|c 2005
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 08.03.2005
|
| 500 |
|
|
|a Date Revised 01.12.2018
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a CD1d-restricted natural killer T (NKT) cells are involved in the regulation of various immune responses, and have been shown to inhibit viral replication in animal hepatitis models when activated by the glycolipid alpha-galactosylceramide (alpha-GalCer, KRN7000). Previous studies have indicated that alpha-GalCer-induced activation of the immune system requires both CD1d expression by antigen-presenting cells as well as (normal) numbers of NKT cells. Discrepancies exist over circulating numbers of human invariant Valpha24+Vbeta11+ NKT cells during hepatitis C virus (HCV) infection. Here, by cross-sectional analysis and longitudinal analysis of patients undergoing effective combination antiviral therapy, we demonstrate that circulating Valpha24+Vbeta11+ NKT cell numbers are not decreased during active HCV infection. Importantly, as we also show that CD1d is expressed at comparable levels by peripheral blood monocytes and CD1c+ myeloid dendritic cells (DC) of healthy individuals and HCV-infected patients, these data indicate that all ingredients for evaluating the antiviral effects of the Valpha24+Vbeta11+ NKT cell ligand alpha-GalCer in HCV-infected patients are present
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antigens, CD1
|2 NLM
|
| 650 |
|
7 |
|a Antigens, CD1d
|2 NLM
|
| 650 |
|
7 |
|a Antiviral Agents
|2 NLM
|
| 650 |
|
7 |
|a CD1D protein, human
|2 NLM
|
| 650 |
|
7 |
|a Interferon alpha-2
|2 NLM
|
| 650 |
|
7 |
|a Interferon-alpha
|2 NLM
|
| 650 |
|
7 |
|a RNA, Viral
|2 NLM
|
| 650 |
|
7 |
|a Recombinant Proteins
|2 NLM
|
| 650 |
|
7 |
|a Polyethylene Glycols
|2 NLM
|
| 650 |
|
7 |
|a 3WJQ0SDW1A
|2 NLM
|
| 650 |
|
7 |
|a Ribavirin
|2 NLM
|
| 650 |
|
7 |
|a 49717AWG6K
|2 NLM
|
| 650 |
|
7 |
|a peginterferon alfa-2b
|2 NLM
|
| 650 |
|
7 |
|a G8RGG88B68
|2 NLM
|
| 700 |
1 |
|
|a Molling, Johan W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a von Blomberg, B Mary E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kölgen, Wendy
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Stam, Anita G
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a de Gruijl, Tanja D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mulder, Chris J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Janssen, Harry L A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nishi, Nobusuke
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a van den Eertwegh, Alfons J M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Scheper, Rik J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a van Nieuwkerk, Carin J M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 114(2005), 2 vom: 10. Feb., Seite 183-9
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:114
|g year:2005
|g number:2
|g day:10
|g month:02
|g pages:183-9
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 114
|j 2005
|e 2
|b 10
|c 02
|h 183-9
|